• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    6/12/25 9:16:55 AM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    ftre-20250610
    0001965040FALSE00019650402025-06-102025-06-100001965040us-gaap:CommonClassAMember2025-06-102025-06-100001965040us-gaap:PreferredClassAMember2025-06-102025-06-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    June 10, 2025
    Date of Report (Date of earliest event reported)

    Fortrea Holdings Inc.
    (Exact Name of Registrant as Specified in its Charter)


    Delaware
    001-41704
    92-2796441
    (State or other jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    8 Moore Drive
    Durham,
    North Carolina
    27709
    (Address of principal executive offices)
    (Zip Code)

    (Registrant’s telephone number including area code) 877-495-0816

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act.
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par valueFTREThe Nasdaq Stock Market LLC
    Rights to Purchase Series A Preferred Stock, par value $0.001 per share-The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 10, 2025, Fortrea Holdings Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders, upon the recommendation of the Company’s Board of Directors (the “Board”), approved the amendment and restatement of the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan (the “Incentive Plan” and, as amended and restated, the “A&R Incentive Plan”). The A&R Incentive Plan, among other things, increased the number of shares of the Company’s common stock under the Incentive Plan by 6,500,000 shares, provided for minimum vesting periods, provided that no dividends or dividend equivalents payable or credited with respect to restricted stock, restricted stock units or performance share awards or other awards will be paid until the underlying award vests, eliminated liberal share recycling with respect to full-value awards under the Incentive Plan and made certain other administrative changes to the Incentive Plan.

    A summary of the A&R Incentive Plan was also included as part of Proposal 4 in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 28, 2025 (the “Proxy Statement”). The foregoing descriptions of the A&R Incentive Plan provided herein and contained in the Proxy Statement are qualified in their entirety by reference to the full text of the A&R Incentive Plan, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    As of April 17, 2025, the record date for the Annual Meeting, there were 90,540,317 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. Of these shares, 82,888,659 were present or represented by proxy, which constituted a quorum for the transaction of business at the Annual Meeting. Proxies for the meeting were solicited in accordance with Regulation 14A under the Securities Exchange Act of 1934, as amended. At the Annual Meeting, stockholders voted on the following proposals:

    Proposal 1: Election of Directors

    The following nominees were elected to the Board to serve as Class II Directors until the Company’s 2028 Annual Meeting of Stockholders based on the following votes:

    VotesVotesVotesBroker
    For AgainstAbstainedNon-Votes
    Dr. Amrit Ray 63,349,1667,852,794333,65911,353,040
    Erin L. Russell 68,271,9713,214,08349,56511,353,040
    Machelle Sanders62,641,8948,843,81249,91311,353,040

    Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

    The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based upon the following votes:

    VotesVotesVotes
    For AgainstAbstained
    82,675,784114,33998,536

    Proposal 3: Advisory Vote on the Compensation of the Company’s Named Executive Officers

    The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was approved based upon the following votes:

    VotesVotesVotesBroker
    For AgainstAbstainedNon-Votes
    68,050,2813,302,818182,52011,353,040



    Proposal 4: Approval of the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan, as Amended and Restated

    The proposal to amend and restate the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan was approved by the following final voting results:

    VotesVotesVotesBroker
    For AgainstAbstainedNon-Votes
    67,787,6643,586,743161,21211,353,040





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Fortrea Holdings Inc.
    By:
    /s/ Stillman Hanson
    Name: Stillman Hanson
    Title: General Counsel and Secretary
    Date: June 12, 2025



    Get the next $FTRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    12/6/2024$28.00 → $25.00Outperform → Neutral
    Robert W. Baird
    9/25/2024$25.00 → $21.00Buy → Hold
    Jefferies
    8/8/2024$31.00 → $27.00Outperform → In-line
    Evercore ISI
    7/24/2024$30.00Equal Weight
    Barclays
    6/6/2024$28.00Neutral
    Goldman
    More analyst ratings

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fortrea Adopts Limited-Duration Stockholder Rights Plan

      DURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that its Board of Directors (the "Board") has unanimously adopted a limited-duration stockholder rights plan ("Rights Plan") to protect the best interests of all Fortrea stockholders. The Rights Plan is effective immediately and will expire on June 10, 2026, unless terminated earlier by the Board. The Rights Plan is intended to enable the Company's stockholders to realize the long-term value of their investment, ensure that all stockholders receive fair and equal treatment in the event of any proposed takeover of the Company, and to

      6/12/25 8:36:04 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Names Anshul Thakral Chief Executive Officer

      DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the "Board") named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable gr

      6/11/25 4:10:24 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea to Present at the Jefferies Global Healthcare Conference

      DURHAM, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chairman and Interim Chief Executive Officer, Peter M. Neupert and Chief Financial Officer, Jill McConnell will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:45 am ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the event. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and

      6/3/25 4:05:12 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/24 6:28:42 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • Pike Thomas bought $248,066 worth of shares (10,000 units at $24.81), increasing direct ownership by 21% to 57,827 units (SEC Form 4)

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      5/30/24 4:34:01 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

      DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

      2/20/25 7:00:00 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

      SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

      12/5/24 4:05:00 PM ET
      $BDX
      $FTRE
      $MRVI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Fortrea Appoints Robert Parks as Chief Accounting Officer

      DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

      7/11/24 8:00:09 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    SEC Filings

    See more
    • Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Fortrea Holdings Inc. (0001965040) (Filer)

      6/12/25 9:16:55 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 8-A12B filed by Fortrea Holdings Inc.

      8-A12B - Fortrea Holdings Inc. (0001965040) (Filer)

      6/12/25 9:12:27 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders

      8-K - Fortrea Holdings Inc. (0001965040) (Filer)

      6/12/25 8:42:52 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fortrea Holdings Inc.

      SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

      11/12/24 9:55:14 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

      SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

      5/28/24 5:10:47 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

      SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

      2/26/24 7:01:18 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Fortrea with a new price target

      Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00

      5/2/25 8:14:26 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea downgraded by Barclays with a new price target

      Barclays downgraded Fortrea from Equal Weight to Underweight and set a new price target of $6.00

      4/10/25 8:49:08 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea downgraded by Citigroup with a new price target

      Citigroup downgraded Fortrea from Buy to Neutral and set a new price target of $23.00 from $30.00 previously

      12/11/24 7:50:50 AM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Russell Erin L

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/25 8:19:06 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Sanders Machelle

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/25 8:18:10 PM ET
      $FTRE
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Smith David Ross

      4 - Fortrea Holdings Inc. (0001965040) (Issuer)

      6/12/25 8:17:01 PM ET
      $FTRE
      Medical Specialities
      Health Care

    $FTRE
    Financials

    Live finance-specific insights

    See more
    • Fortrea Adopts Limited-Duration Stockholder Rights Plan

      DURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that its Board of Directors (the "Board") has unanimously adopted a limited-duration stockholder rights plan ("Rights Plan") to protect the best interests of all Fortrea stockholders. The Rights Plan is effective immediately and will expire on June 10, 2026, unless terminated earlier by the Board. The Rights Plan is intended to enable the Company's stockholders to realize the long-term value of their investment, ensure that all stockholders receive fair and equal treatment in the event of any proposed takeover of the Company, and to

      6/12/25 8:36:04 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Reports First Quarter 2025 Results

      For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai

      5/12/25 6:40:58 AM ET
      $FTRE
      Medical Specialities
      Health Care
    • Fortrea Announces CEO Stepping Down

      DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank

      5/12/25 6:30:02 AM ET
      $FTRE
      Medical Specialities
      Health Care